

Group II, claim 34, drawn to a population of dendritic cell for use in vaccination of a subject produced by the process of (a) obtaining dendritic cells from an individual, (b) causing the dendritic cells to express an antigen by either (i) exposing the dendritic cells to the antigen in culture under conditions promoting uptake and processing of the antigen, or (ii) transfecting the dendritic cells with a gene encoding the antigen; (c) activating the antigen expressing dendritic cells, (d) treating the dendritic cells with an agent that inhibits MINOR expression, wherein **the agent that inhibits MINOR expression is a small molecule**, classifiable in class 514, subclass 2, for example.

Group III, claim 34, drawn to a population of dendritic cell for use in vaccination of a subject produced by the process of (a) obtaining dendritic cells from an individual, (b) causing the dendritic cells to express an antigen by either (i) exposing the dendritic cells to the antigen in culture under conditions promoting uptake and processing of the antigen, or (ii) transfecting the dendritic cells with a gene encoding the antigen; (c) activating the antigen-expressing dendritic cells, (d) treating the dendritic cells with an agent that inhibits MINOR expression, wherein **the agent that inhibits MINOR expression is an inhibitory nucleotide**, classifiable in class 536, subclass 24.5, for example.

In response, Applicants elect for continued examination the invention of Group III, which relates to an agent that is an **inhibitory nucleotide**. Claim 34 encompasses the claimed invention.

Response to Office Action of December 13, 2010

**CONCLUSION**

Applicant submits this paper in response to the Office Action mailed December 13, 2010 in the above-referenced patent application along with a Request for a two-month Extension of Time and requisite fee. Applicant believes that no other fees are required for consideration and entry of this paper. Nevertheless, Applicant hereby authorizes the Director to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) or credit any overpayment to Deposit Account No. 04-1105, under order no. 62763(71699).

Dated: March 14, 2011

Respectfully submitted,

Electronic signature: /Melissa Hunter-Ensor, Ph.D., Esq./  
Melissa Hunter-Ensor, Ph.D., Esq.

Registration No.: 55,289  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 517-5580  
Attorneys/Agents For Applicant